Linked Life Data

17640299

Source:http://linkedlifedata.com/resource/pubmed/id/17640299

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2007-8-13
pubmed:abstractText
Granulocyte colony-stimulating factor (G-CSF)-supported, post-remission chemotherapy (Cx) for adult acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) was evaluated. One hundred and forty-three eligible patients (median age, 41 years) including 126 ALL and 17 LBL receiving induction Cx (vincristine, cyclophosphamide, prednisolone [PSL], doxorubicin, L-asparaginase, intrathecal-methotrexate [IT-MTX]) were analyzed. For patients achieving complete response (CR), two courses of post-remission Cx (course A of daunorubicin, cytosine arabinoside, vindesine, PSL plus IT-MTX; course B of mitoxantrone, etoposide, vincristine, PSL plus IT-MTX) with the use of G-CSF were repeated alternately; thereafter, maintenance Cx including MTX and 6-mercaptopurine was given for 2 years. One hundred and nineteen (83%) patients achieved CR, while 14 (10%) died during induction. Among the 119 patients achieving CR, five died in remission, 76 relapsed, and the remaining 38 were alive without disease. The median survival time of the 143 eligible patients was 26 months (95% confidence interval, 19-34). At a median follow-up time of 9 years, the 5-year survival rate was 32% and the 5-year progression-free survival (PFS) rate was 26%. The 5-year survival rate of 36 patients who underwent autologous (n = 20) or allogeneic stem cell transplantation (SCT; n = 16) in the first CR group was 58%. Compared with the authors' previous trials, survival and PFS were markedly improved. In conclusion, G-CSF-supported, intensive post-remission Cx and subsequent SCT are worthy of further investigation for the treatment of adult ALL and LBL.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1347-9032
pubmed:author
pubmed:issnType
Print
pubmed:volume
98
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1350-7
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:17640299-6-Mercaptopurine, pubmed-meshheading:17640299-Adolescent, pubmed-meshheading:17640299-Adult, pubmed-meshheading:17640299-Aged, pubmed-meshheading:17640299-Antimetabolites, Antineoplastic, pubmed-meshheading:17640299-Combined Modality Therapy, pubmed-meshheading:17640299-Cytarabine, pubmed-meshheading:17640299-Etoposide, pubmed-meshheading:17640299-Female, pubmed-meshheading:17640299-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:17640299-Humans, pubmed-meshheading:17640299-Male, pubmed-meshheading:17640299-Methotrexate, pubmed-meshheading:17640299-Middle Aged, pubmed-meshheading:17640299-Mitoxantrone, pubmed-meshheading:17640299-Precursor Cell Lymphoblastic Leukemia-Lymphoma, pubmed-meshheading:17640299-Stem Cell Transplantation, pubmed-meshheading:17640299-Transplantation, Autologous
pubmed:year
2007
pubmed:articleTitle
Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group Study 9004.
pubmed:affiliation
National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. ktobinai@ncc.go.jp
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II